Positioning High-Throughput CETSA in Early Drug Discovery through Screening against B-Raf and PARP1
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Positioning High-Throughput CETSA in Early Drug Discovery through Screening against B-Raf and PARP1
Authors
Keywords
-
Journal
SLAS Discovery
Volume 24, Issue 2, Pages 121-132
Publisher
SAGE Publications
Online
2018-12-14
DOI
10.1177/2472555218813332
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- In Situ Target Engagement Studies in Adherent Cells
- (2018) Hanna Axelsson et al. ACS Chemical Biology
- Modulation of Protein-Interaction States through the Cell Cycle
- (2018) Lingyun Dai et al. CELL
- Impact of a five-dimensional framework on R&D productivity at AstraZeneca
- (2018) Paul Morgan et al. NATURE REVIEWS DRUG DISCOVERY
- A high content, high throughput cellular thermal stability assay for measuring drug-target engagement in living cells
- (2018) Andrew J. Massey PLoS One
- Homogeneous Assay for Target Engagement Utilizing Bioluminescent Thermal Shift
- (2018) Melanie L. Dart et al. ACS Medicinal Chemistry Letters
- A widely-applicable high-throughput cellular thermal shift assay (CETSA) using split Nano Luciferase
- (2018) Natalia J. Martinez et al. Scientific Reports
- Determining direct binders of the Androgen Receptor using a high-throughput Cellular Thermal Shift Assay
- (2018) Joseph Shaw et al. Scientific Reports
- Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point
- (2017) Richard A. Ward et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of highly selective CRAF inhibitors, 3-carboxamido-2H-indazole-6-arylamide: In silico FBLD design, synthesis and evaluation
- (2016) Waqar Aman et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
- (2016) Y. Pommier et al. Science Translational Medicine
- CETSA screening identifies known and novel thymidylate synthase inhibitors and slow intracellular activation of 5-fluorouracil
- (2016) Helena Almqvist et al. Nature Communications
- The FGFR Inhibitor BGJ398 Has Activity in Tumors with FGFR Alterations
- (2016) Cancer Discovery
- Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
- (2015) Sheng-Bin Peng et al. CANCER CELL
- RAF inhibitors that evade paradoxical MAPK pathway activation
- (2015) Chao Zhang et al. NATURE
- Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma
- (2015) Teresa E. Williams et al. ACS Medicinal Chemistry Letters
- Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5- a ] pyrazine G-479
- (2014) Kirk D. Robarge et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors
- (2014) Piro Lito et al. CANCER CELL
- PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation
- (2014) A A Mian et al. LEUKEMIA
- The cellular thermal shift assay for evaluating drug target interactions in cells
- (2014) Rozbeh Jafari et al. Nature Protocols
- Determining target engagement in living systems
- (2013) Gabriel M Simon et al. Nature Chemical Biology
- Tumor adaptation and resistance to RAF inhibitors
- (2013) Piro Lito et al. NATURE MEDICINE
- Appraising iniparib, the PARP inhibitor that never was—what must we learn?
- (2013) Joaquin Mateo et al. Nature Reviews Clinical Oncology
- Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
- (2013) D. M. Molina et al. SCIENCE
- Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
- (2013) E. J. Morris et al. Cancer Discovery
- Role of PARP Inhibitors in Cancer Biology and Therapy
- (2012) D. Davar et al. CURRENT MEDICINAL CHEMISTRY
- CEP-32496: A Novel Orally Active BRAFV600E Inhibitor with Selective Cellular and In Vivo Antitumor Activity
- (2012) J. James et al. MOLECULAR CANCER THERAPEUTICS
- The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease but promotes renal and hepatic fibrosis
- (2011) B. Buchholz et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search